GLAESNER, WOLFGANG,MILLICAN, ROHN, LEE, JR,VICK, ANDREW, MARK
申请号：
HK11103498.8
公开号：
HK1149566B
申请日:
2011.04.06
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
Disclosed are specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
